5 terminated. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 2 | Terminated 2 |
Follow Metastasis: new trials by email Literature Review of Metastasis trials Research Report on Metastasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) THOR-707, Checkpoint inhibitor, anti-EGFR antibody - Metastasis | Phase 1 / Phase 2 | Terminated | Synthorx, Inc, a Sanofi company | 175 | 2019-06-20 | 2025-12-15 |
| Pembrolizumab + Idelalisib for Lung Cancer Study Pembrolizumab, Idelalisib - Non Small Cell Lung Cancer, Metastasis | Phase 1 / Phase 2 | Terminated | Asha Nayak | 4 | 2017-09-26 | 2024-02-28 |
| CEST- Glucose Enhanced MRI for Metastatic Brain Tumours Magnetic resonance imaging, Gadovist (Gadobutrol), 50% dextrose solution - Brain Neoplasms, Malignant, Metastasis | Phase 2 | Terminated | British Columbia Cancer Agency | 3 | 2016-10-01 | 2019-01-28 |
| A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer ZD4054 - Prostate Cancer, Metastasis | Phase 2 | Terminated | Aarhus University Hospital | 24 | 2009-10-01 | 2014-01-08 |
| Study of GPX-100 in the Treatment of Metastatic Breast Cancer GPX-100 (13-deoxydoxorubicin) - Breast Cancer, Metastasis | Phase 2 | Terminated | Gem Pharmaceuticals | 40 | 2005-03-01 | 2007-01-09 |
Neoplasm Metastasis (5) · Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Prostatic Neoplasms (1) · Recurrence (1)
Neoplastic Processes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Neoplasms by Site (4) · Neoplasms (3) · Brain Diseases (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Disease Attributes (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1)
pembrolizumab (2) · Cetuximab (1) · Magnetic Resonance Spectroscopy (1) · ZD4054 (1) · gadobutrol (1) · idelalisib (1)
Aarhus University Hospital (1) · Asha Nayak (1) · British Columbia Cancer Agency (1) · Gem Pharmaceuticals (1) · Synthorx, Inc, a Sanofi company (1)
United States (3) · Argentina (1) · Australia (1) · Bulgaria (1) · Canada (1) · Chile (1) · Denmark (1) · Singapore (1) · Spain (1)
John H. Ward, MD (1) · Michael Borre, MD Phd DMSc (1) · Michael McKenzie (1) · Zhonglin Hao, MD, PhD (1)
2023 (1)